Abstract: In one embodiment, a method includes determining available media content from one or more content sources and providing at least a portion of the available media content for display in a programming guide on a display device of a user. The programming guide includes a plurality of entries each associated with one of the available media content. The method further includes determining that an update action button should be displayed on the display device, providing the update action button for display on the display device when it is determined that the update action button should be displayed, and updating the programming guide in response to a user selection of the update action button. The update action button is operable to cause the social-networking system to update the programming guide.

Abstract: The present invention is directed to methods of inhibition, delay of formation, treatment, prophylaxis and/or prevention of infections caused by bacteria that exhibit tolerance to antimicrobial agents, including slow growing, stationary-phase and biofilm forming bacteria, through the use of glycopeptide antibiotics, such as oritavancin.

Abstract: In one embodiment, a method includes determining available media content from one or more content sources and providing at least a portion of the available media content for display in a programming guide on a display device of a user. The programming guide includes a plurality of entries each associated with one of the available media content. The method further includes determining that an update action button should be displayed on the display device, providing the update action button for display on the display device when it is determined that the update action button should be displayed, and updating the programming guide in response to a user selection of the update action button. The update action button is operable to cause the social-networking system to update the programming guide.

Abstract: Methods of treating bacterial infections in a subject using a synergistic combination of oritavancin and a polymyxin are disclosed.

Abstract: The present invention is directed to methods of treating a bacterial infection in a subject through the administration of a therapeutically effective amount of a glycopeptide antibiotic to a subject having a bacterial infection. The effective amount of the glycopeptide antibiotic that is administered to the subject provides a fraction of the glycopeptide antibiotic administered to the subject bound to serum proteins within the subject and within a selected range.

Abstract: Methods of treating bacterial infections in a subject using oritavancin, including bacteremia, osteomyelitis and endocarditis, are disclosed.

Abstract: Methods of treating bacterial infections in a subject using a synergistic combination of oritavancin and a polymyxin are disclosed.

Abstract: Glycopeptide antibiotics, such as oritavancin, demonstrate significant activity against B. anthracis. Methods for the treatment, prophylaxis and prevention of B. anthracis infection and disease in animals, including humans, are described.

Abstract: Glycopeptide antibiotics, such as oritavancin, demonstrate significant activity against a wide range of bacteria. Methods for the treatment, prophylaxis and prevention of bacterial infection and disease in animals, including humans, using a single dose of oritavancin over the course of therapy, are described.

Abstract: The present invention is directed to methods of treating a bacterial infection in a subject through the administration of a therapeutically effective amount of a glycopeptide antibiotic to a subject having a bacterial infection. The effective amount of the glycopeptide antibiotic that is administered to the subject provides a fraction of the glycopeptide antibiotic administered to the subject bound to serum proteins within the subject and within a selected range.

Abstract: Glycopeptide antibiotics, such as oritavancin, demonstrate significant activity against a wide range of bacteria. Methods for the treatment, prophylaxis and prevention of bacterial infection and disease in animals, including humans, using a single dose of oritavancin over the course of therapy, are described.

Abstract: The present invention is directed to methods of inhibition, delay of formation, treatment, prophylaxis and/or prevention of infections caused by bacteria that exhibit tolerance to antimicrobial agents, including slow growing, stationary-phase and biofilm forming bacteria, through the use of glycopeptide antibiotics, such as oritavancin.

Abstract: Glycopeptide antibiotics, such as oritavancin, demonstrate significant activity against B. anthracis. Methods for the treatment, prophylaxis and prevention of B. anthracis infection and disease in animals, including humans, are described.